When combined with immunotherapy, an mRNA-based vaccine has been found to cut the risk of melanoma recurrence and distant metastasis more than immunotherapy alone.
Results from the phase 3 trial of the vaccine, called intismeran, will be presented at an international medical meeting and shared with regulatory authorities, according to an Aug. 19 news release from Moderna.
“Intismeran in combination with Keytruda as adjuvant therapy demonstrated statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared to Keytruda alone for patients with completely resected stage 2B, 2C, 3 or 4 cutaneous melanoma who had not undergone prior treatment with systemic therapy,” the release said.
The vaccine was jointly developed by Merck and Moderna.
A previous study led by researchers at New York City-based NYU Langone Health and its Perlmutter Cancer Center found the vaccine cut the risk of melanoma recurrence by 49% when combined with immunotherapy.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
